Vitamin D and Clinical Outcomes in Dialysis

Seminars in Dialysis

Volumn 28, Issue 6, 2015, Pages 604-609

  Parikh, Coral ^a   Gutgarts, Victoria ^a   Eisenberg, Elliot ^a   Melamed, Michal L ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25-HYDROXYVITAMIN D; PARATHYROID HORMONE; VITAMIN D;

ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLOOD; COMPLICATION; HUMAN; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; RENAL REPLACEMENT THERAPY; VITAMIN D DEFICIENCY;

HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; PARATHYROID HORMONE; RENAL DIALYSIS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84945920859     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/sdi.12446     Document Type: Article

References (67)

1. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, et al.: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72:1004-1013, 2007
2. Bikle DD, Gee E, Halloran B, Kowalski MA, Ryzen E, Haddad JG: Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab 63:954-959, 1986
3. Bhan I, Powe CE, Berg AH, Ankers E, Wenger JB, Karumanchi SA, et al.: Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int 82:84-89, 2012
4. Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, et al.: Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 369:1991-2000, 2013
5. Raisz LG, Trummel CL, Holick MF, DeLuca HF: 1, 25-dihydroxycholecalciferol: a potent stimulator of bone resorption in tissue culture. Science 175:768-769, 1972
6. Brumbaugh PF, Haussler MR: 1 Alpha, 25-dihydroxycholecalciferol receptors in intestine. I. Association of 1 alpha, 25-dihydroxycholecalciferol with intestinal mucosa chromatin. J Biol Chem 249:1251-1257, 1974
7. de Boer IH, Sachs MC, Chonchol M, Himmelfarb J, Hoofnagle AN, Ix JH, et al.: Estimated GFR and circulating 24, 25-dihydroxyvitamin D3 concentration: a participant-level analysis of 5 cohort studies and clinical trials. Am J Kidney Dis 64:187-197, 2014
8. Muntner P, Jones TM, Hyre AD, Melamed ML, Alper A, Raggi P, et al.: Association of serum intact parathyroid hormone with lower estimated glomerular filtration rate. Clin J Am Soc Nephrol 4:186-194, 2009
9. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, et al.: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79:1370-1378, 2011
10. Takahashi F, Finch JL, Denda M, Dusso AS, Brown AJ, Slatopolsky E: A new analog of 1, 25-(OH)2D3, 19-NOR-1, 25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 30:105-112, 1997
11. Coyne DW, Grieff M, Ahya SN, Giles K, Norwood K, Slatopolsky E: Differential effects of acute administration of 19-Nor-1, 25-dihydroxy-vitamin D2 and 1, 25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 40:1283-1288, 2002
12. Coyne DW, Goldberg S, Faber M, Ghossein C, Sprague SM: A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. Clin J Am Soc Nephrol 9:1620-1626, 2014
13. Jamaluddin EJ, Gafor AH, Yean LC, Cader R, Mohd R, Kong NC, et al.: Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol 18:507-514, 2014
14. Baker LR, Abrams L, Roe CJ, Faugere MC, Fanti P, Subayti Y, et al.: 1, 25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int 35:661-669, 1989
15. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321:274-279, 1989
16. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 17(113):S1-S130, 2009
17. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF: Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev Oct 7;4:CD005633, 2009
18. Cozzolino M, Ketteler M, Martin KJ, Sharma A, Goldsmith D, Khan S: Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study. Nephrol Dial Transplant 29:899-905, 2014
19. Melamed ML, Thadhani RI: Vitamin D therapy in chronic kidney disease and end stage renal disease. Clin J Am Soc Nephrol 7:358-365, 2012
20. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, et al.: Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16:1115-1125, 2005
21. Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, et al.: Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 70:351-357, 2006
22. Duranton F, Rodriguez-Ortiz ME, Duny Y, Rodriguez M, Daures JP, Argiles A: Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis. Am J Nephrol 37:239-248, 2013
23. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, et al.: Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 19:179-184, 2004
24. Tsujimoto Y, Tahara H, Shoji T, Emoto M, Koyama H, Ishimura E, et al.: Active vitamin D and acute respiratory infections in dialysis patients. Clin J Am Soc Nephrol 6:1361-1367, 2011
25. Sarathy H, Pramanik V, Kahn J, Abramowitz MK, Meier K, Kishore P, et al.: The effects of short-term vitamin D supplementation on glucose metabolism in dialysis patients: a systematic review and meta-analysis. Int Urol Nephrol 47:537-549, 2015
26. Li L, Lin M, Krassilnikova M, Ostrow K, Bader A, Radbill B, et al.: Effect of cholecalciferol supplementation on inflammation and cellular alloimmunity in hemodialysis patients: data from a randomized controlled pilot trial. PLoS ONE 9:e109998, 2014
27. Wasse H, Huang R, Long Q, Zhao Y, Singapuri S, McKinnon W, et al.: Very high-dose cholecalciferol and arteriovenous fistula maturation in ESRD: a randomized, double-blind, placebo-controlled pilot study. J Vasc Access 15:88-94, 2014
28. Afsar B, Agca E, Turk S: Comparison of erythropoietin resistance in hemodialysis patients using calcitriol, cinacalcet, or paricalcitol. J Clin Pharmacol 2015 Jun 1. doi: 10.1002/jcph.556. [Epub ahead of print]
29. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208-2218, 2004
30. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al.: Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52:519-530, 2008
31. Slinin Y, Foley RN, Collins AJ: Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 16:1788-1793, 2005
32. Tentori F, Wang M, Bieber BA, Karaboyas A, Li Y, Jacobson SH, et al.: Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol 10:98-109, 2015
33. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al.: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584-592, 2008
34. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446-456, 2003
35. Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, et al.: Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 70:1858-1865, 2006
36. Tentori F, Albert JM, Young EW, Blayney MJ, Robinson BM, Pisoni RL, et al.: The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 24:963-972, 2009
37. Zheng Z, Shi H, Jia J, Li D, Lin S: Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies. BMC Nephrol 14:199, 2013
38. Mann MC, Hobbs AJ, Hemmelgarn BR, Roberts DJ, Ahmed SB, Rabi DM: Effect of oral vitamin D analogs on mortality and cardiovascular outcomes among adults with chronic kidney disease: a meta-analysis. Clin Kidney J 8:41-48, 2015
39. Gorriz JL, Molina P, Cerveron MJ, Vila R, Bover J, Nieto J, et al.: Vascular calcification in patients with nondialysis CKD over 3 years. Clin J Am Soc Nephrol 10:654-666, 2015
40. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, et al.: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87:E10-E17, 2000
41. Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA: Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 19:1509-1519, 2008
42. Cardus A, Panizo S, Parisi E, Fernandez E, Valdivielso JM: Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 22:860-866, 2007
43. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, et al.: Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 288:E125-E132, 2005
44. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP: 1, 25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229-238, 2002
45. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, et al.: Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307:674-684, 2012
46. Wang AY, Fang F, Chan J, Wen YY, Qing S, Chan IH, et al.: Effect of paricalcitol on left ventricular mass and function in CKD-the OPERA trial. J Am Soc Nephrol 25:175-186, 2014
47. Tamez H, Zoccali C, Packham D, Wenger J, Bhan I, Appelbaum E, et al.: Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J 164:902-909, 2012 e2.
48. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, et al.: Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 302:1782-1789, 2009
49. Bals R, Weiner DJ, Moscioni AD, Meegalla RL, Wilson JM: Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect Immun 67:6084-6089, 1999
50. Zasloff M: Antimicrobial peptides, innate immunity, and the normally sterile urinary tract. J Am Soc Nephrol 18:2810-2816, 2007
51. Gombart AF, Bhan I, Borregaard N, Tamez H, Camargo CA Jr, Koeffler HP, et al.: Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin Infect Dis 48:418-424, 2009
52. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al.: Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311:1770-1773, 2006
53. Quraishi SA, De Pascale G, Needleman JS, Nakazawa H, Kaneki M, Bajwa EK, et al.: Effect of Cholecalciferol Supplementation on Vitamin D Status and Cathelicidin Levels in Sepsis: a Randomized, Placebo-Controlled Trial. Crit Care Med 43:1928-1937, 2015
54. Kerschbaum J, Vychytil A, Lhotta K, Prischl FC, Wiesholzer M, Machhold-Fabrizii V, et al.: Treatment with oral active vitamin D is associated with decreased risk of peritonitis and improved survival in patients on peritoneal dialysis. PLoS ONE 8:e67836, 2013
55. de Boer IH: Vitamin D and glucose metabolism in chronic kidney disease. Curr Opin Nephrol Hypertens 17:566-572, 2008
56. Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A, Prager R, Franek E, et al.: Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 53:1343-1347, 1998
57. Hung AM, Ikizler TA: Factors determining insulin resistance in chronic hemodialysis patients. Contrib Nephrol 171:127-134, 2011
58. Maestro B, Campion J, Davila N, Calle C: Stimulation by 1, 25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J 47:383-391, 2000
59. Norman AW, Frankel JB, Heldt AM, Grodsky GM: Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 209:823-825, 1980
60. Boquist L, Hagstrom S, Strindlund L: Effect of 1.25-dihydroxycholecalciferol administration on blood glucose and pancreatic islet morphology in mice. Acta Pathol Microbiol Scand A 85:489-500, 1977
61. Mak RH: Intravenous 1, 25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int 41:1049-1054, 1992
62. Mak RH: Amelioration of hypertension and insulin resistance by 1, 25-dihydroxycholecalciferol in hemodialysis patients. Pediatr Nephrol 6:345-348, 1992
63. Mak RH: 1, 25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int 53:1353-1357, 1998
64. Hung AM, Sundell MB, Plotnikova NE, Bian A, Shintani A, Ellis CD, et al.: A pilot study of active vitamin D administration and insulin resistance in African American patients undergoing chronic hemodialysis. J Renal Nutr 23:185-193, 2013
65. Kandula P, Dobre M, Schold JD, Schreiber MJ Jr, Mehrotra R, Navaneethan SD: Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 6:50-62, 2011
66. Hewitt NA, O'Connor AA, O'Shaughnessy DV, Elder GJ: Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients. Clin J Am Soc Nephrol 8:1143-1149, 2013
67. Bhan I, Dobens D, Tamez H, Deferio JJ, Li YC, Warren HS, et al.: Nutritional vitamin D supplementation in dialysis: a randomized trial. Clin J Am Soc Nephrol 10:611-619, 2015